All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 1, 2017, Pages 115-126

  Reddy, K R ^a   Lim, J K ^a   Kuo, A ^a   Di Bisceglie, A M ^a   Galati, J S ^a   Morelli, G ^a   Everson, G T ^a   Kwo, P Y ^a   Brown, R S ^a   Sulkowski, M S ^a   Akuschevich, L ^a   Lok, A S ^a   Pockros, P J ^a   Vainorius, M ^a   Terrault, N A ^a   Nelson, D R ^a   Fried, M W ^a   Manns, M P ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; DATA BASE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PHOTOSENSITIVITY; PRIORITY JOURNAL; RASH; RECURRENCE RISK; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; FACTUAL DATABASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; INTERNATIONAL COOPERATION; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERNATIONALITY; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

EID: 84996599822     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13823     Document Type: Article

References (33)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36: S21–9.
2. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809–16.
3. Davis GL, Alter MJ, El–Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513–21 e6.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264–73 e1.
5. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271–8.
6. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509–16 e1.
7. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584–93.
8. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886–93.
9. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44: 1675–84.
10. Forns X, Bruix J. Treating hepatitis C in patients with cirrhosis: the effort is worth it. J Hepatol 2010; 52: 624–6.
11. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology, 2015; 148: 108–17.
12. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100–7 e1.
13. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2014; 61: 1485–94.
14. Jacobson I, Poordad F, Firpi-Morell R, et al. O008: efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A). J Hepatol 2015; 62: S193–4.
15. Foster G, McLauchlan J, Irving W, et al. O002: treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol 2015; 62: S190–1.
16. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685–97.
17. OLYSIO (Simeprevir) Capsules: Package Insert. Titusville, NJ: Janssen Therapeutics, 2013. Available at https://www.olysio.com/shared/product/olysio/prescribing-information.pdf (accessed 18 Aug 2016).
18. SOVALDI (Sofosbuvir) Tablets: Package Insert. Foster City, CA: Gilead Sciences, 2013. Available at http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf (accessed 18 Aug 2016).
19. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. Hepatology 2013; 58: 1379A–80A.
20. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756–65.
21. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–81.
22. Banerjee D, Reddy K. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016; 43: 674–96.
23. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274–87.
24. Burton JR, Everson GT. Management of the transplant recipient with chronic hepatitis C. Clin Liver Dis 2013; 17: 73–91.
25. Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004–12.
26. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–59.
27. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62: 715–25.
28. Foster GR, Irving WL, Cheung M, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64: 1224–31.
29. Lutchman G, Nguyen N, Chang C, et al. Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. Aliment Pharmacol Ther 2016; 44: 738–46.
30. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403–13.
31. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993–2001.
32. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878–87.
33. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–77.